CIR
NTLA icon

Clear Investment Research’s Intellia Therapeutics NTLA Stock Holding History

Clear Investment Research’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11
Closed -$335 – 251
2023
Q4 		$335 Buy
+11
New +$316 ﹤0.01% 260

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Clear Investment Research's NTLA Position: Q1 2024 in Review

Clear Investment Research sold out of Intellia Therapeutics (NTLA) in Q1 2024, closing a stake of 11 shares — an estimated $335 sold.

Clear Investment Research first reported a position in NTLA in Q4 2023 and held it in 1 quarter. The position peaked at $335 in Q4 2023. 284 funds tracked by Wall St. Rank hold NTLA as of Q1 2024.

  • Clear Investment Research reported no remaining Intellia Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Clear Investment Research sold 11 Intellia Therapeutics shares in Q1 2024, an estimated $335.
  • Clear Investment Research first reported a position in Intellia Therapeutics in Q4 2023 and held it in 1 quarter.
  • Clear Investment Research's Intellia Therapeutics position peaked at $335 in Q4 2023.
  • 284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2024.

Based on Clear Investment Research's 13F filing for Q1 2024, filed 2 May 2024.